CEO Ron Bentsur is scheduled to speak at 10:30 a.m. ET in New York; Nuvectis says a webcast will be available in the ...
Avacopan (Tavneos), the complement pathway inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis ...
Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.
Michel Michaelides, MD, discusses phase 3 DRAGON results showing that oral tinlarebant slowed atrophic lesion growth by about ...
This Week's Pharma News] Shionogi's 315.6 Billion Yen Acquisition, Ono Pharmaceutical's IgG Degrader Licensing, Asahi Kasei's ...
A new PLOS Pathogens study finds that the microRNA-1246 regulates macrophage lipid metabolism and helps explain why some ...
CBD could help strengthen a light-based cancer treatment’s ability to destroy tumor cells, according to a new scientific ...
By merging bulk and single-cell RNA sequencing with machine learning and lab experiments, researchers have identified smooth ...
A recent study suggests mRNA vaccines can make some tumours more responsive to immunotherapy, lowering the risk of death ...
New clearance strategies and humanized cell models are giving researchers faster tools to confront biology’s unusually ...
Australia expands pan-tumor immunotherapy access to nivolumab/ipilimumab and pembrolizumab, introducing a broader ...
Agreement Lonza Expands Dual-Payload ADC Technology Offering Through Exclusive Access to Qurient’s CDK7 Inhibitors 12.10.2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results